The company remains on track to deliver net income and positive cash flows for full year 2025. Positive cash flow refers to the improvement in cash, cash equivalents, restricted cash and investments from year end 2024 to year end 2025, not including the impact of $125 million in Pharmakon prepayments made in 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCRX:
- BioCryst reports Q2 EPS 15c, consensus 3c
- BCRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- BioCryst Announces New President Amid Leadership Change
- BioCryst announces planned retirement of CEO Stonehouse, Gayer to succeed
- BioCryst Pharmaceuticals’ BCX9930 Study Termination: Implications for Investors